Latest Financial Results

Q3 2017

Quarterly Results

Ended Sep 30, 2017

Stock Information

NASDAQ: XBIO Xenetic Biosciences, Inc.
Price
Change
Volume
Day Range
52 Week Range

Company Overview

We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Our lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Further, the Company's proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The Company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

Contact Information

Investor Relations
Jenene Thomas Communications, LLC.
Jenene Thomas
T: 908-996-0239
jtc@jtcir.com

Transfer Agent
Empire Stock Transfer, Inc.
1859 Whitney Mesa Drive
Henderson, NV 89014
T: 702-818-5898